Guidebook on selecting mRNA raw materials | Thermo Fisher Scientific

The SARS-CoV-2 crisis, and the prophylactic mRNA vaccines developed in response to it, brought mRNA to the forefront as an exciting new frontier in medicine. Developers looking to unlock the potential of mRNA therapeutics, however, must overcome a significant challenge—selecting and sourcing raw materials that will allow them to create a consistent therapeutic product at scale.

In this guidebook, developed in collaboration with BioPharma Dive, we share insights into:

The role raw materials play in supporting consistency in process development
The importance of quality control and the downstream ramifications of choosing suboptimal materials
How drug developers can evaluate materials and suppliers to find solutions that meet their needs

First name

Last name

Company / institution

Country / region

Zip / postal code

City

Phone number (optional)

What is your current stage of mRNA production? In early stages (research & discovery) Investigating solutions Actively establishing Already performing Not working in mRNA production

Would you like to discuss options for mRNA raw materials with our representative? Yes, I’d like to be contacted. No, I’m here for learning.

I would like Thermo Fisher Scientific (including its affiliates) to add me to a list to receive information about events, products, services and promotions which Thermo Fisher believes may be of interest to me via the following channels:

Phone

I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com

I acknowledge Thermo Fisher Scientific (including its affiliates) willl process my Personal Information according to its Privacy Policy, which includes information about my rights.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.

Guidebook: Achieving consistency in process development of mRNA therapeutics